Juno Therapeutics Competitors and Similar CompaniesClear all
Juno Therapeutics's competitors and similar companies include H3 Biomedicine, Immatics, Kite Pharma and Adaptive Biotechnologies.
 Juno Therapeutics Juno Therapeutics is a clinical-stage company, which develops immunotherapies for the treatment of cancer. |  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. |  Adaptive Biotechnologies Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease. | |||
Founding Date | Founding Date 2013 | Founding Date 2011 | Founding Date N/A | Founding Date 2009 | Founding Date 2009 |
Type | Type Subsidiary | Type Subsidiary | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Seattle, US HQ Göttingen, DE Göttingen, DE München, DE München, DE Bothell, US Brisbane, US | Locations Cambridge, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Santa Monica, US HQ Hoofddorp, NL London, GB El Segundo, US Emeryville, US Frederick, US Oceanside, US see more | Locations Seattle, US HQ New York, US South San Francisco, US |
Employees | Employees 1091% decrease | Employees 378% decrease | Employees 29723% increase | Employees 3,9671% decrease | Employees 70910% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.1 b | Valuation ($) N/A | Valuation ($) 694.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $111.9m (FY, 2017) | Revenue (est.) N/A | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $277m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $71.4m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit €53m (FY, 2025) | Gross profit N/A | Gross profit $205.6m (FY, 2025) |
Net income | Net income ($437.1m) (FY, 2017) | Net income N/A | Net income (€196.4m) (FY, 2025) | Net income N/A | Net income ($59.5m) (FY, 2025) |
Operating ⚠ | |||||
Trademarks (US) | Trademarks (US) N/A | Trademarks (US) 3 (Jul, 2021) | Trademarks (US) N/A | Trademarks (US) 19 (Jan, 2024) | Trademarks (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 310m | Total funding raised $ 200m | Total funding raised $ 267.3m | Total funding raised $ 85.3m | Total funding raised $ 525m |
For sources of this data, please see the company profile
View Company Profiles
H3 Biomedicine
HQ
Cambridge, US
H3 Biomedicine is a biopharmaceutical company that specializes in cancer genomics.
View companyImmatics
HQ
Tübingen, DE
Employees
297↑ 23% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View company
Kite Pharma
HQ
Santa Monica, US
Kite Pharma is a company developing cancer immunotherapy products based on cell therapy.
View companyAdaptive Biotechnologies
HQ
Seattle, US
Employees
709↓ 10% decrease
Adaptive Biotechnologies (formerly known as Adaptive TCR) is a company that develops diagnostics and therapeutic tools based on the immune response to disease.
View company